Background: Variable adherence to assigned conditions is common in randomized clinical trials.
OVERVIEW OF PROBLEM AND APPROACH
Variable adherence to assigned condition is commonplace in randomized clinical trials (RCTs). Oftentimes, variable adherence is endogenous in nature, being driven by patient self-selection. A variety of statistical methods have been developed for the purpose of estimating consistently the cause-and-effect (causal) relationship between observed adherence and the clinical outcome of interest in the presence of unobserved confounding factors induced by endogeneity. 1, 2 Here we propose a generalized modeling framework that, for the first time, combines 2-stage residual inclusion and nonparametric random-coefficients modeling to provide comprehensive adjustment for time-varying and time-invariant unobserved confounding within estimates of the causal effect of variable adherence for longitudinal sampling structures. This extension to longitudinal sampling structures is important because many RCTs monitor longitudinal outcomes on participants. By definition, RCTs assign participants to 2 or more conditions. The proposed modeling framework provides adjustment for time-varying and timeinvariant unobserved confounding within each assigned condition of the RCT (see the Simultaneous Adjustment section).
Instrumental Variables (IV)
Under variable adherence, an intention-to-treat (ITT) 3 analysis gives estimates of treatment effectiveness (ie, effect of treatment "as assigned" sensu Ten Have et al). 4 However, the ITT estimate has limited clinical utility because it does not address response to the amount of treatment as actually received. 5 ITT analysis forgoes the opportunity to capitalize on a possible opportunity to estimate dose response from outcome data collected under variable adherence. Consistent estimation of dose response is complicated by possible confounders-factors which cause variation in adherence and cause variation in outcome. An example is "confounding by indication" 6 wherein a participant adjusts adherence based on current medical status per medical advice. Various methods to address confounding have been proposed, including propensity scores, 7-9 G-estimation, 10 and IV. 11 IV methods are among those that offer a distinct advantage of permitting consistent estimation of dose response in the presence of unobserved confounders, which is an important property because few, if any, situations may exist where investigators can be certain that all possible confounders have been measured. For this reason, we have incorporated IVs as a central component of our proposed modeling framework.
IV methods need to satisfy certain assumptions to generate consistent estimates of the causal effect of an intervention under variable adherence (ie, the "local average treatment effect" among compliers, LATEC). 12 These assumptions need to be considered in each specific application of IV methods. The first assumption is that the IV must cause exposure to intervention and the second is that IVs affect outcome only indirectly through exposure to intervention (exclusion restriction). 13 A third assumption is that IV and outcome have no common causes. As Hernán and Robins 13 explain, the random assignment mechanism satisfies all 3 of these conditions especially, regarding exclusion restriction, under double-blind RCTs. True random assignment is unquestionably exogenous and often associated strongly with degree of adherence to assigned condition. Unusual circumstances may arise where this may not be true, such as in the presence of "defiers," 14 participants predisposed to adhering to whichever assigned condition they are not assigned, which would violate the fourth requisite IV assumption of "monotonicity." 13 A fifth assumption is that randomized units (eg, patients or clusters) have mutually independent potential outcomes ("stable unit treatment value assumption," SUTVA). 14, 15 For present purposes, SUTVA is assumed to apply.
Longitudinal Structure
The current literature on the development and application of IV methods to variable adherence is active and broad. [16] [17] [18] [19] [20] Slower to develop have been models, methods of estimation, and example IV applications to hierarchical sampling structures, including longitudinal, despite the fact that many RCTs collect longitudinal measurements on major outcomes within participants across study visits. Much existing work on longitudinal IV methods, especially earlier studies, focused on the limited circumstance in which adherence is coded as a binary presence-absence variable, 21 which may be due to the fact that, in general, early literature on adjustment for variable adherence emphasized binary measures of adherence. In reality, adherence often varies across a gradation of levels. Bond et al 11 allow for multilevel adherence in a longitudinal setting. They discuss application through generalized least squares (GLS) and employ generalized estimating equations (GEE) 22 in their worked example. Lamiraud et al 23 also employed GEE.
GEE and GLS are marginal models, providing estimates of causal effects of treatment as received on average across the population. 24 Despite recent interest with "population health," 25 population-average estimates are offpurpose for most RCTs, where the goal is to understand how individual patients respond to treatment dosing. 26 In contrast to GEE and GLS, random-coefficients models 24 are well suited for characterizing individual patient response, because they offer estimates of longitudinal response trajectories of individual patients and of the average patient. Only under a linear model do estimates of population-average effects and average-patient effects coincide 24 ; but many settings require a nonlinear modeling framework (eg, binary outcome), which generalized linear random-coefficients models and nonlinear random-coefficients models 27 accommodate. To improve upon existing marginal modeling and/or linear modeling approaches, the method presented here employs random-coefficients models with allowance for nonlinear functional structure (see the Random Coefficients and Model Specification sections) and participant-level random coefficients.
Random Coefficients
To date, random coefficients (random effects) have been employed only rarely to aid estimation of the LATEC. Sitlani et al 28 assumed that random coefficients capture latent factors that are explanatory of endogenous selection to an assigned surgical intervention. Small et al 15 adjusted for variable adherence in the setting of a binary outcome. Lamiraud et al 23 employed a correlated random-coefficients 29 structure. Correlated random coefficients are a very flexible structure because separate participant-level random coefficients could be employed for adherence and for outcome with these 2 random coefficients allowed to covary. A covariance structure is also specified at the level of individual observations. A shared random coefficients 29 specification is another possibility. 28 Within our proposed modeling framework we assume, as in previous literature, 28 that random coefficients capture latent factors that are explanatory of endogenous selection. We go even further and recognize that the presence of unobserved confounders can, probably often, result in complex distributions for random coefficients. Specifically, unobserved confounders can generate a mixture distribution. We model that complexity in a first-stage equation with adherence as the outcome regressed on randomized condition as an instrument with a nonparametric distribution for random intercepts. 30, 31 Rather than shared or correlated random coefficient modeling, we employ the predicted values of these first-stage random intercepts as a fixed (latent effects) covariate in the secondstage equations for the efficacy outcome. Using first-stage random coefficients as a second-stage fixed covariate conditions the second stage on the first and thereby eliminates the need for specification of a between-equation covariance structure, thereby simplifying model formulation. Secondstage equations regress the efficacy outcome on these predicted first-stage random intercepts and observed adherence. This facilitates adjustment for unobserved confounders (captured by the first-stage random coefficient) that are invariant across repeated measures as a form of two-stage residual inclusion (TSRI). 32 Including the same predicted random coefficient values in both stages should avoid unnecessary introduction of inconsistency into the estimate of the causal effect of variable adherence. 11 
TSRI
TSRI has been shown to provide a consistent estimate of the causal effect of interest under linear and nonlinear model structures. 30 Indeed, TSRI addresses the concern raised by Lamiraud et al 23 about application of IV methods to nonlinear settings. In addition to adjustment for time-invariant unobserved confounding, our method also employs the first-stage residuals as an additional fixed covariate in second-stage efficacy equations to offer adjustment for timevarying unobserved confounders thereby providing compound, TSRI, instrumental variable estimation (cTSRI-IV). Details are provided in the Methods section.
Simultaneous Adjustment
RCTs by definition consist of 2 or more conditions to which participants are assigned. The dose-response relationship between treatment as received and efficacy outcome may be potentially obscured by endogenous selection (and unobserved confounding) in some or all assigned conditions; and the precise nature of endogenous selection can easily vary among these conditions. Our system of equations (see the Model Specification section) permits simultaneous and condition-specific estimation of the LATEC for each and every of the study conditions to which participants are randomly assigned in the RCT. This efficient use of data from a RCT may be particularly helpful in application to comparative effectiveness studies, which are a class of RCT designs that are seeing widening use in efforts to enhance equipoise.
METHODS

Model Specification
Parameters, random variables, and observed values will be denoted by uppercase Greek letters, uppercase Roman letters, and lowercase Roman letters, respectively. Let random variable A kit denote adherence to the randomly assigned study condition k for person i, i = {1,y,n}, at time t; and let random variable O kit denote outcome for condition k, person i at time t. Randomly assigned conditions are indexed by k, k = {1,y,k}, 2rk. To simplify exposition here, we assume randomization is to 2 assigned conditions, k2, which allows illustration of the basic method and simplification of some notation. (Extension to 2 < k is straightforward.) For 1rg 1 < g 2 , models for the expectations of A kit and O kit are given by the following system of equations (ie, k 2 f1; 2g for adherence and for outcome):
where g and ǵ k are some continuous real-valued mappings from R to R (eg, link functions). The respective first-stage and second-stage participant-level random coefficient are R ki and Ŕ ki . The term a kit -m ki provides residual inclusion to adjust for time-varying endogeneity effect e k for the kth assigned condition; B k provides residual inclusion to adjust for time-invariant endogeneity effect B k for the kth assigned condition, with requisite inverse transformation g À 1 ; and x pkit is the pth covariate measured on the ith person at time t in the kth condition. Covariates may include interactions with assigned condition and with time. Typically, m ki will be a single equation, whereas the y ki can be formulated as a separate equation for each assigned condition. All first-stage covariates are included in the second stage as main effects to avoid introduction of bias. 11 Defining Z kit def A kit Àm ki and Z kit def O kit Ày ki , take
and 
Random coefficients and residuals are independent between assigned conditions due to randomized assignment; and random coefficients and residuals are independent between stages due to residual inclusion (conditioning). As (1c) does not account for longitudinal structure, we specify (1d) ð1eÞ Together, (1a) through (1e) constitute a completely general formulation to permit cTSRI-IV estimation for k2. The choice of mappings, covariates, any further restrictions on the covariance structure, as well as statistical distributions for adherence, outcomes, and random coefficients will be specific to each application; and, as indicated above, models can be specified for 2 < k. Specific model structures are illustrated in the Simulation Studies and the Results section.
Parameter Estimation
Various approaches to cTSRI-IV estimation of the parameters of model 1 are possible. Here maximum likelihood estimation is employed for its efficiency and availability. Let C k denote the first-stage (adherence outcome) expectation parameters and Ć k denote the second-stage (efficacy outcome) expectation parameters. Respective observed adherence and efficacy outcome vectors are a k and o k for assigned condition k. We appropriately condition on the random coefficients such that the resultant generalized sequence of likelihood specifications are
ð2bÞ Because we wish to place no further restrictions on the distribution of the R ki , estimation of (2a) is through an expectation-maximization (EM) algorithm. 31, 32 The EM algorithm is initiated by drawing initial values for the random coefficients from a mixture of normal distributions, although final predictions r ki resulting from application of the EM algorithm need not have a distribution that is a mixture of normal distributions. Use of an EM algorithm is intuitively appealing because it is designed to recover latent structures, in this case latent confounders. Likelihoods (2a) and (2b) can be combined as a product (due to independence between assigned conditions and conditioning in the second stage) for estimation purposes but that only offers an efficiency advantage in terms of reduced variance of parameter estimates if the second-stage model for the efficacy outcome shares a common parameter with the first-stage model for the adherence outcome-a restriction that may often not be warranted on scientific grounds. Nor do we wish to necessarily have common parameters across assigned conditions in the second stage, although this option could explored. A sequential estimation procedure is illustrated in the Simulation Studies and the Results section.
The structure of model 1 can induce strong correlation among A kit , Z kit , and R ki . This multicollinearity complicates second-stage (efficacy outcome) parameter estimation. In addition to second-stage predictors a kit , z kit , and r ki , this multicollinearity can also encompass the second-stage intercept. Regularization approaches such as a ridge penalty are one possibility (see the Statistical Implications section), although, without care, these may introduce bias. In the Simulation Studies through the Findings section, we apply an alternative strategy that combines orthogonalization and white-noise data augmentation 33 to mitigate multicollinearity's impact on finite-sample bias and variance.
Simulation Studies
A set of 96 simulation studies were conducted to assess small-sample bias properties of the proposed cTSRI-IV estimator. All studies assumed a RCT with 1:1 random assignment of participants to 2 different conditions and participants observed at 6 visits that were regularly spaced in time. Each participant's dose was simulated as a linear function of a fixed intercept term a 0 = 100, a random participant-specific intercept term Z i $ iid N 0; 25 ð Þ, participant's age a 1 ¼ For each simulated dataset, contrasting approaches were used for fitting. The "naive" approach entailed a single-stage regression of the efficacy outcome on dose, the dose by condition interaction, visit, and the visit by condition interaction. Fitting employed either a linear mixed-coefficients model for- mulation with fixed coefficients for the 4 covariates, normally distributed random intercepts and residuals, and estimation through restricted maximum likelihood for g 0 k Á ð Þ ¼ 1 or, in the simulations under nonlinear structure, a generalized linear mixed-coefficients model formulation with fixed coefficients for the 4 covariates, normally distributed random intercepts, logarithm link, and estimation through adaptive Gaussian quadrature. The cTSRI-IV approach was in 2 stages. The first stage was a linear mixed-coefficients model formulation with fixed coefficients for condition, visit and their interaction; nonparametrically distributed random intercepts; normally distributed residuals; and estimation through the EM algorithm, initiated with a mixture of 2 normal distributions for the random intercepts. (In practice, different mixture quantities are applied and goodness-of-fit assessed, with the quantity of components dependent upon the structure of the time-invariant latent confounders). The second stage entailed fitting a separate fixed-coefficients generalized linear mixed model for each assigned condition. For each of these 2 models, the efficacy outcome was regressed on dose, visit, the participant's firststage predicted value for the random intercept, and the participant's first-stage predicted residual values. Second-stage residuals were assumed to be normally (or log normally) distributed, as designed. Multicollinearity was addressed through a combination of Gram-Schmidt orthogonalization of r ki with respect to a kit and white-noise augmentation of the intercept vector as 1 + lw, for tuning constant 0 < l, where w is a 6Â n element vector of pseudorandom independent draws from a standard normal distribution. Constant l will need to be optimized in each application. Settings too close to zero cause failure in convergence of the optimization algorithm, whereas settings too far from zero increase bias and variance of the estimate of the LATEC. In general, l should be employed as an algorithm convergence tuning parameter and set to a value just large enough to provide reliable algorithm convergence. We present results for settings of l = 0.01 for the linear model and l 2 0:01; 0:25 ½ for the nonlinear model. Nonparametric fixed effects modeling was performed using the nplmreg package in R version 3.2. 34 We found that the trust-region optimization algorithm, with central finite difference derivative approximation and a small initial trust-region radius (eg, < 0.01), available in the nlmixed procedure in SAS version 9.4 (SAS Institute, Cary, NC), gave algorithm convergence failures below 4.7% and 13.5% during simulations for linear and nonlinear models, respectively. Second-stage random coefficients were predicted through Laplace approximation. Because neither the naive approach nor cTSRI-IV estimation explicitly included age nor I it as covariates, these served as unobserved time-invariant and time-varying confounders, respectively. Code for simulation studies is available upon request (T.H.H.).
RESULTS
Simulation Results
Results of the 96 simulation studies are summarized in Table 1 . Compared with the naive estimator, cTSRI-IV estimation reduced bias in estimates of adherence dosage in all but a few rare cases (gray cells in Table 1 ). Bias reduction was greatest for higher levels of residual variance (c 2 = 20). Among cTSRI-IV estimates, bias reduction was consistently greater for a time-varying confounder than the time-invariant confounder. Bias reduction was similar across linear and nonlinear models.
The APPLES Trial
Application of the cTSRI-IV estimator is demonstrated using data from a RCT in sleep medicine. The Apnea Positive Pressure Long-term Efficacy Study (APPLES) was a multicenter, clinical trial sponsored by the National Heart, Lung and Blood Institute, in which 1105 participants were randomized at a 1:1 ratio to either continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) or to a sham device. 35 Per the study's protocol, each participant was to complete baseline screening and diagnostic testing, be randomized to sham or active, and followed for 6 months. All participants provided informed consent. The study protocol was approved by the Institutional Review Board at each of 5 participating centers. All analyses reported here employed completely de-identified data. Three primary neurocognitive outcomes, corresponding to each of 3 major domains of neurocognitive function (attention and vigilance, learning and memory, and executive/frontal lobe function), were assessed prerandomization (baseline) and at 2-and 6-month visits during the active intervention period: the Buschke Selective Reminding Test-Sum Recall (BSRT-SR), the Pathfinder Number Test-Total Time (Trails A of Trail Making Test; PFNT-TT), and the primary mid-day score from the Sustained Working Memory Test-Overall Mid-Day Index (SWMT-OMI). 36 Greater neurocognitive ability is indicated by higher scores for BSRT-SR and SWMT-OMI and lower scores for PFNT-TT. Here we restrict analysis to the PFNT-TT as the efficacy outcome. A total of 849 participants had data at the 2-and 6-month visits for the analysis presented here, n 1 = 412 for sham and n 2 = 437 for active. Information about the impact of missing data due to dropout is detailed in Kushida et al. 35 All analyses described in the remainder of the Results section were performed in SAS version 9.4 (SAS Institute) and R. 34 
cTSRI-IV Estimation for APPLES
Participants in APPLES were randomized to 2 assigned conditions, so k = 2 as in the Model Specification section. Separately for each of these 3 outcomes, we fit model 1 with the following tailoring to APPLES:
and
Here k = 1 for sham and k = 2 for active. Covariates {x 2 , x 3, x 4, x 5 } are those used to construct randomization strata: race (nonwhite x 2 = 0, white x 2 = 1), sex (female x 3 = 0, male x 3 = 1), moderately severe OSA at baseline (x 4 = 1, x 4 = 0 otherwise), and severe OSA at baseline (x 5 = 1, x 5 = 0 otherwise). Baseline age in years is also a covariate (x 6 ). Age is a potentially strong confounder. In our experience, adherence often tends to increase with participants' ages in RCTs. In addition, performance on neurocognitive measures can decline with age. For purposes of exposition, this model assumes a common LATEC across the subpopulations defined by the covariates. The common LATEC assumption can be relaxed 11 and indeed this possibility should be examined in a complete analysis, including for the APPLES trial. Random coefficients Ŕ ki BN (0, ś 2 k1 ) are also included in the second stage to account for possible correlation between the 2 repeated measurements. All parameter estimates are time averages across the 2-and 6-month visits. Alternative formulations that allow for interaction with time are also possible. Specification (3b) assumes that repeated measurements on the same outcome (adherence or a neurocognitive measure) within a person are uncorrelated conditional upon the random coefficient R ki . We assume Z kit $ N 0; s
where f½Á denotes the normal density, j½Á denotes the gamma density, f 2 is the density function for an unspecified distribution where the subscript indicates a 2-component mixture density, and k 2 1; 2 f g.
Model Fitting and Hypothesis Testing
Adherence was measured nightly as hours of device usage per night through a monitor built into the sham and active CPAP devices (Encore Pro SmartCard; Phillips Respironics Inc., Andover, MA) and formulated as the average nightly value over the prior 2 months. Approximately 21% and 29% of nightly adherence data were missing at 2 and 6 months, respectively, yielding the sample size of 849 participants for fitting model 3. For present analysis, missing status was assumed to be noninformative (ie, due to monitor malfunction) so that 2-month averages were calculated using only observed adherence values. Alternative approaches could entail some form of imputation, including setting missing values to zero assuming the participant was not using the device.
Parameters were estimated by separately optimizing each of the 3 likelihood equations (4a) and (4b) using the trust-region optimization algorithm for (4b), as described in the Simulation Studies section, with an initial trust-region radius setting of 0.01; and we found l = 0.01 provided reliable optimization algorithm convergence. Second-stage random coefficients were predicted through Laplace approximation. To propagate sampling error properly from the first stage into the second, we employed bootstrap resampling stratified on assigned condition. From 1000 bootstrap resamples we calculated simple percentile 95% confidence bounds. Table 2 reports estimates of bootstrap 95% confidence intervals from the fit of model 3 to the PFNT-TT efficacy outcome data from APPLES. Results suggest that an increasing dose of active adherence decreases (improves) average PFNT-TT scores, a finding not detected in the absence of cTSRI-IV estimation in the original report. 35 The distribution of second-stage efficacy residuals were somewhat skewed (sample skewness = 1.46) and strongly leptokurtic (sample kurtosis = 7.89), indicating a violation of the model's assumption that these residuals are drawn from a Gaussian distribution. We suggest possible remedies in the Statistical Implications section.
Findings
DISCUSSION
Statistical Implications
The proposed method addresses estimation of the causal effect of treatment as received (LATEC) under possibly nonlinear and longitudinal model structures. Reduction in bias due to unobserved confounding is provided through isolation and adjustment for exogenous and endogenous components of adherence through time-invariant and time-variant residual inclusion (TSRI). Adjustment for observed confounders, such as age and known comorbidities, is also essential. Age may be useful because adherence and health outcomes often vary among RCT participants of differing ages. Altogether, this especially comprehensive approach to adjustment for unobserved confounders should effectively mitigate inconsistency in estimates of the LATEC in RCTs of longitudinal sampling structures, as our simulation studies suggest.
A potential drawback to comprehensive adjustment for unobserved confounders is that the cTSRI-IV model is enriched in fixed parameters, especially with incorporation of interaction terms and/or spline bases for covariates. When sample sizes are modest, identification of model parameters may oftentimes require further restrictions on those parameters. One general approach would be to add a L q -penalty term (eg, q = 1 for lasso or q = 2 for ridge regression) to the likelihood (equation 2) or, even better, apply these penalties to derived inputs such as principal components 37 as an additional means for addressing multicollinearity. This approach comes with additional computational complexity as penalty parameters may need be estimated through sample reuse procedures. 37 Further, additional sample reuse procedures, such as bootstrapping, 38 would be needed to generate confidence intervals on parameter estimates that propagate sampling error in the penalty parameter estimate into LA-TEC estimates. To minimize introduction of bias into the estimate of the LATEC, the LATEC parameters could be excluded from the penalty term. Penalized estimation of the LATEC under the cTSRI-IV model merits study.
The cTSRI-IV model also contains random components (random effects and residuals). The standard approach to modeling random coefficients is to assume that these coefficients follow a Gaussian distribution. We propose a nonparametric finite mixture alternative to account for the overdispersion induced by the latent confounder(s). Another nonparametric approach is generalized maximum entropy estimation. 39 Generalized maximum entropy estimation can be useful for small-sample sizes, in the presence of multicollinearity among covariates, and can also accommodate residual distributions that are skewed or strongly leptokurtic (see the Findings section). 40 Bayesian estimation is yet another alternative and an attractive one in a parameter-rich setting because, like generalized maximum entropy estimation, Bayesian estimation permits borrowing information about parameters from prior published studies through empirically informed priors 41 ; and Bayesian estimation can employ finite mixtures to model complex (eg, leptokurtic) residual distributions.
We employ a nonparametric bootstrap procedure for constructing confidence intervals on model parameters (see the Model Fitting and Hypothesis Testing section) to accommodate the possibly nonlinear structure of the model and 2-stage estimation procedure. Various standard diagnostics, bias correctives, and efficiency gains are available for the nonparametric bootstrap, 42 including those that allow for residual heteroscedasticity, 43 so that, altogether the nonparametric bootstrap allows proper inference without sacrificing flexibility of model structure.
Limitations
The list of assumptions for consistent IV estimates of dose response is not short (see the Instrumental Variables section). Among those assumptions is that the IV impacts outcome only indirectly through exposure to intervention (exclusion restriction). This should result if the RCT is effectively double blinded. 13 APPLES was designed as a double-blind study; yet, analysis of exit interviews suggested that some participants, especially in the sham condition, may have been aware of their assigned condition, although overall degree of agreement between assigned and blinded guesses was poor. 34 Another assumption, SUTVA, will not hold if some participants interfere with other participants' outcomes through social interactions. 44 
CONCLUSIONS
We introduce a method for estimating the causal effects of treatment as received simultaneously for each assigned condition of a RCT within a framework that permits nonlinear modeling of longitudinal data structures. A comprehensive approach to adjustment for unobserved confounders is included. Future work could explore asymptotic properties of the proposed estimator and the implications of stochastic adherence. 45 
